drug

ALKS 9072, High

as of 2026-07-01
Add to landscapeMonitor thisCompare thisAsk about this
at a glance
small molecule
Pre-approval / investigational in the US
Developed by Alkermes, Inc.
1 trials in the graph
Synthesized from structured facts only — each point cited above.

Mechanism & identity

Modality
small molecule

Indications

Investigational (via trials)
SchizophreniaSchizophrenia

Trials

1
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
NCT01626456Phase 3Completed

KOLs & investigators

1
Alkermes Medical Director, MD

Facts & assertions

0 sourced
No assertions recorded for this entity.
relationships
The graph out of here
developer
Alkermes, Inc.
company
trial
A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070)
PHASE3
trial
indication
Schizophrenia
indication
Schizophrenia
indication
KOL
Alkermes Medical Director, MD
KOL score —
person